Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study.
Yildirim HC, Kapar C, Koksal B, Seyyar M, Sanci PC, Guliyev M, Perkin P, Buyukkor M, Yaslikaya S, Majidova N, Keskinkilic M, Ozaskin D, Avci T, Gunes TK, Arcagok M, Topal A, Keskin GSY, Kavgaci G, Yildirim N, Celayir OM, Avci N, Aslan F, Alkan A, Erciyestepe M, Cengiz M, Pehlivan M, Gulmez A, Beypinar I, Basoglu Tuylu T, Kayikcioglu E, Chalabiyev E, Turhal S, Guzel HG, Ayas E, Sahbazlar M, Dulgar O, Demir H, Yavuzsen T, Bayoglu V, Kivrak Salim D, Ozturk B, Ozdemir F, Kara O, Oksuzoglu B, Bal O, Demirci NS, Yilmaz M, Cabuk D, Aksoy S. Yildirim HC, et al. Among authors: yildirim n. J Chemother. 2024 Mar 18:1-7. doi: 10.1080/1120009X.2024.2330835. Online ahead of print. J Chemother. 2024. PMID: 38497444
Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes.
Esin E, Oksuzoglu B, Bilici A, Cicin I, Kostek O, Kaplan MA, Aksoy S, Aktas BY, Ozdemir O, Alacacioglu A, Cabuk D, Sumbul AT, Sakin A, Paydas S, Yetisir E, Er O, Korkmaz T, Yildirim N, Sakalar T, Demir H, Artac M, Karaagac M, Harputluoglu H, Bilen E, Erdur E, Degirmencioglu S, Aliyev A, Cil T, Olgun P, Basaran G, Gumusay O, Demir A, Tanrikulu E, Yumuk PF, Imamoglu I, Oyan B, Cetin B, Haksoyler V, Karadurmus N, Erturk I, Evrensel T, Yilmaz H, Beypinar I, Kocer M, Pilanci KN, Seker M, Urun Y, Yildirim N, Eren T, Demirci U; Turkish Oncology Group. Esin E, et al. Among authors: yildirim n. Cancer Chemother Pharmacol. 2019 Jan;83(1):131-143. doi: 10.1007/s00280-018-3712-7. Epub 2018 Oct 30. Cancer Chemother Pharmacol. 2019. PMID: 30377778
Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study.
Taşçı EŞ, Kutlu Y, Ölmez ÖF, Mutlu AU, Gündoğdu Y, Seyyar M, Şahin E, Çabuk D, Majidova N, Uğurlu İ, Demirci A, Aydın D, Çavdar E, Bayram S, Yıldırım N, Karataş F, Eryılmaz MK, Çağlayan D, Menekşe S, Kut E, Arak H, Keser M, Sunar V, Perkin P, Şakalar T, Oyan B, Sönmez Ö, Özer L, Yıldız İ. Taşçı EŞ, et al. Among authors: yildirim n. Expert Opin Pharmacother. 2024 Mar;25(4):477-484. doi: 10.1080/14656566.2024.2337261. Epub 2024 Apr 3. Expert Opin Pharmacother. 2024. PMID: 38568074
Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG).
Akyildiz A, Guven DC, Koksal B, Karaoglan BB, Kivrak D, Ismayilov R, Aslan F, Sutcuoglu O, Yazici O, Kadioglu A, Alan O, Majidova N, Erciyestepe M, Ozcan E, Akdag G, Taban H, Kaya AO, Guliyev M, Yildirim N, Sakalar T, Yazilitas D, Unal C, On S, Biter S, Demirci NS, Senler FC, Kemal Y, Halil OD, Gullu I, Aksoy S. Akyildiz A, et al. Among authors: yildirim n. Eur Arch Otorhinolaryngol. 2024 Sep;281(9):4991-4999. doi: 10.1007/s00405-024-08744-4. Epub 2024 May 25. Eur Arch Otorhinolaryngol. 2024. PMID: 38795147 Free PMC article.
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study.
Beypınar İ, Demir H, Yaslıkaya Ş, Köşeci T, Demir B, Çolak G, Ağaoğlu AB, Şahbazlar M, Şancı PC, Çabuk D, Işık U, Şahin E, Coşkun A, Caner B, Aykut T, Artaç M, Duygulu ME, Sever N, Öksüz S, Turan N, Aykan MB, Tüzün EK, Uysal M, Uğurlu İ, Sakin A, Acar C, Özaşkın D, Şakalar T, Keskinkılıç M, Yavuzşen T, Köse N, Ertürk İ, Yıldırım N, Balçık OY, Alkan A, Selvi O, Erçin E, Ünal OÜ, Karaçin C. Beypınar İ, et al. Among authors: yildirim n. Breast Cancer Res Treat. 2024 Dec;208(3):597-604. doi: 10.1007/s10549-024-07456-x. Epub 2024 Aug 9. Breast Cancer Res Treat. 2024. PMID: 39123071
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study.
Özyurt N, Alkan A, Gülbağcı B, Seyyar M, Aydın E, Şahbazlar M, Türker M, Kınıkoğlu O, Yerlikaya T, Dinç G, Aytaç A, Kalkan Z, Ebinç S, Gültürk İ, Keskinkılıç M, İşleyen ZS, Çağlayan D, Türkel A, Aydın E, Şakalar T, Sekmek S, Yıldırım N, Koçak S, Okutur K, Özveren A, Dursun B, Kitaplı S, Eren OÖ, Beypınar İ, Hacıbekiroğlu İ, Çabuk D, Karaman E, Acar Ö, Paydaş S, Eryılmaz MK, Demir B, Oruç Z, Yılmaz M, Biricik FS, Salim DK, Tanrıverdi Ö, Doğan M. Özyurt N, et al. Among authors: yildirim n. Sci Rep. 2024 Oct 9;14(1):23556. doi: 10.1038/s41598-024-75293-5. Sci Rep. 2024. PMID: 39384975 Free PMC article.
Enzyme Inhibitory, Physicochemical, and Phytochemical Properties and Botanical Sources of Honey, Bee Pollen, Bee Bread, and Propolis Obtained from the Same Apiary.
Gercek YC, Dagsuyu E, Basturk FN, Kırkıncı S, Yıldırım N, Kıskanç G, Özmener B, Unlu YS, Kalkan SN, Boztaş K, Oz GC, Yanardağ R, Bayram NE, Kostić AŽ. Gercek YC, et al. Among authors: yildirim n. Antioxidants (Basel). 2024 Dec 5;13(12):1483. doi: 10.3390/antiox13121483. Antioxidants (Basel). 2024. PMID: 39765812 Free PMC article.
De-Escalation of Nodal Surgery in Clinically Node-Positive Breast Cancer.
Cabioglu N, Koçer HB, Karanlik H, Gülçelik MA, Igci A, Müslümanoglu M, Uras C, Mantoglu B, Trabulus DC, Akgül G, Tükenmez M, Senol K, Özkurt E, Sen E, Karadeniz Çakmak G, Bademler S, Emiroglu S, Yildirim N, Kara H, Dag A, Dilege E, Altinok A, Basaran G, Varol E, Ugurlu Ü, Bölükbasi Y, Ersoy YE, Zengel B, Karaman N, Özbas S, Zer L, Gül Kiliç H, Agcaoglu O, Sakman G, Utkan Z, Soyder A, Akcan A, Ergün S, Yilmaz R, Aydiner A, Soran A, Ibis K, Özmen V. Cabioglu N, et al. Among authors: yildirim n. JAMA Surg. 2025 Jan 2. doi: 10.1001/jamasurg.2024.5913. Online ahead of print. JAMA Surg. 2025. PMID: 39745737
Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03.
Cabioglu N, Karanlik H, Igci A, Muslumanoglu M, Gulcelik MA, Uras C, Kocer HB, Trabulus DC, Ozkurt E, Cakmak GK, Tukenmez M, Bademler S, Yildirim N, Akgul GG, Sen E, Senol K, Emiroglu S, Citgez B, Ersoy YE, Dag A, Zengel B, Basaran G, Kara H, Dilege E, Ugurlu MU, Celik A, Ilgun S, Bolukbasi Y, Karaman N, Sakman G, Ozbas S, Kilic HG, Polat AK, Ozemir IA, Kilic B, Altınok A, Varol E, Dogan L, Akcan A, Ozcinar B, Zer L, Soyder A, Velidedeoglu M, Erozgen F, Goktepe B, Dogan M, Kebudi A, Yigit B, Celik B, Yormaz S, Arici C, Agcaoglu O, Sevinc AI, Atahan MK, Valiyeva V, Baran E, Aljorani I, Utkan Z, Yeniay L, Kivilcim T, Soran A, Aydiner A, Ibis K, Ozmen V. Cabioglu N, et al. Among authors: yildirim n. Ann Surg Oncol. 2025 Feb;32(2):952-966. doi: 10.1245/s10434-024-16472-6. Epub 2024 Dec 2. Ann Surg Oncol. 2025. PMID: 39623189
473 results